In focus · trending topic

immuno-oncology

120 stories · following the connections

Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab

By Nasdaq OMXFeb 25, 2016, 9:05 PM UTC

Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates

By Nasdaq OMXFeb 9, 2016, 1:00 PM UTC

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

By Nasdaq OMXFeb 2, 2016, 1:16 PM UTC

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences

By Nasdaq OMXJan 20, 2016, 1:05 PM UTC

TESARO Outlines Business Priorities and Strategic Outlook for 2016

By Nasdaq OMXJan 11, 2016, 1:15 PM UTC

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

By Nasdaq OMXJan 6, 2016, 1:05 PM UTC

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

By Nasdaq OMXDec 7, 2015, 9:05 PM UTC

Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015

By Nasdaq OMXDec 3, 2015, 9:05 PM UTC